MXPA02010627A - Derivados de 2-acil-indol y su uso como farmaco antitumoral. - Google Patents

Derivados de 2-acil-indol y su uso como farmaco antitumoral.

Info

Publication number
MXPA02010627A
MXPA02010627A MXPA02010627A MXPA02010627A MXPA02010627A MX PA02010627 A MXPA02010627 A MX PA02010627A MX PA02010627 A MXPA02010627 A MX PA02010627A MX PA02010627 A MXPA02010627 A MX PA02010627A MX PA02010627 A MXPA02010627 A MX PA02010627A
Authority
MX
Mexico
Prior art keywords
tumour agents
derivatives
indol derivatives
acyl indol
acyl
Prior art date
Application number
MXPA02010627A
Other languages
English (en)
Inventor
Thomas Klenner
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE2000120852 external-priority patent/DE10020852A1/de
Priority claimed from DE2001102629 external-priority patent/DE10102629A1/de
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of MXPA02010627A publication Critical patent/MXPA02010627A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invencion comprende nuevos derivados de indol y heteroindol de la formula general I (ver formula I) sus tautomeros, estereoisomeros, mezclas y sales, su preparacion y el uso de derivados de indol de la formula general I como farmacos antitumorales.
MXPA02010627A 2000-04-28 2001-04-27 Derivados de 2-acil-indol y su uso como farmaco antitumoral. MXPA02010627A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000120852 DE10020852A1 (de) 2000-04-28 2000-04-28 2-Acryl-indolderivate und deren Verwendung als Antitumormittel
DE2001102629 DE10102629A1 (de) 2001-01-20 2001-01-20 2-Acyl-indolderivate und deren Verwendung als Antitumormittel
PCT/EP2001/004783 WO2001082909A2 (de) 2000-04-28 2001-04-27 2-acyl-indolderivate und deren verwendung als antitumormittel

Publications (1)

Publication Number Publication Date
MXPA02010627A true MXPA02010627A (es) 2004-05-17

Family

ID=26005501

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02010627A MXPA02010627A (es) 2000-04-28 2001-04-27 Derivados de 2-acil-indol y su uso como farmaco antitumoral.

Country Status (27)

Country Link
US (2) US20020091124A1 (es)
EP (1) EP1276720B1 (es)
JP (1) JP2004501092A (es)
KR (1) KR20030024661A (es)
CN (1) CN1286810C (es)
AR (1) AR029915A1 (es)
AT (1) ATE348805T1 (es)
AU (1) AU783459B2 (es)
BG (1) BG107309A (es)
BR (1) BR0110414A (es)
CA (1) CA2407677A1 (es)
CZ (1) CZ20023544A3 (es)
DE (1) DE50111690D1 (es)
EE (1) EE200200607A (es)
GE (1) GEP20063751B (es)
HK (1) HK1054549B (es)
HR (1) HRP20020940A2 (es)
HU (1) HUP0300480A3 (es)
IL (1) IL152477A0 (es)
IS (1) IS6594A (es)
MX (1) MXPA02010627A (es)
NO (1) NO20025150L (es)
NZ (1) NZ522246A (es)
PL (1) PL358877A1 (es)
RU (1) RU2002132253A (es)
SK (1) SK15432002A3 (es)
WO (1) WO2001082909A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1289952A1 (en) 2000-05-31 2003-03-12 AstraZeneca AB Indole derivatives with vascular damaging activity
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
DE10152306A1 (de) * 2001-10-26 2003-07-24 Asta Medica Ag 2-Acylindolderivate mit neuen therapeutisch wertvollen Eigenschaften
JP2005532280A (ja) 2002-04-03 2005-10-27 アストラゼネカ アクチボラグ 化合物
TW200400177A (en) 2002-06-04 2004-01-01 Wyeth Corp 1-(Aminoalkyl)-3-sulfonylindole and-indazole derivatives as 5-hydroxytryptamine-6 ligands
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
SE0300908D0 (sv) * 2003-03-31 2003-03-31 Astrazeneca Ab Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
WO2005056547A2 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
US7589206B2 (en) 2004-06-09 2009-09-15 Glaxo Group Limited Pyrrolopyridine derivatives
BRPI0517549A (pt) * 2004-10-05 2008-10-14 Merz Pharma Gmbh & Co Kgaa novas propenonas cìclicas e acìclicas para o tratamento de distúrbios do snc
NZ556686A (en) * 2005-02-14 2010-01-29 Bionomics Ltd Novel tubulin polymerisation inhibitors
US20070155738A1 (en) 2005-05-20 2007-07-05 Alantos Pharmaceuticals, Inc. Heterobicyclic metalloprotease inhibitors
BRPI0609802A2 (pt) * 2005-05-20 2017-05-02 Alantos Pharmaceuticals Holding Inc composto, composição farmacêutica e uso de um composto
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
FR2950053B1 (fr) * 2009-09-11 2014-08-01 Fournier Lab Sa Utilisation de derives d'indole benzoique comme activateurs de nurr-1, pour le traitement de la maladie de parkinson
WO2014033497A1 (en) * 2012-08-27 2014-03-06 Centre National De La Recherche Scientifique 5-azaindole compounds with anticancer and antiangiogenic activities
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
JP6820854B2 (ja) * 2015-01-18 2021-01-27 エスアールアイ インターナショナルＳＲＩ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ｍａｐ４ｋ４（ｈｇｋ）インヒビター
CN104945376B (zh) * 2015-07-09 2017-03-15 安徽理工大学 一种3‑芳酰基吲哚化合物的合成方法
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
CN107722013B (zh) * 2016-08-11 2021-01-12 中国科学院上海药物研究所 去氮嘌呤类化合物及其药物组合物、制备方法和用途
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3660430A (en) * 1969-11-04 1972-05-02 American Home Prod 2-substituted-3-arylindoles
US3838167A (en) * 1972-08-01 1974-09-24 Lilly Co Eli Process for preparing indoles
DK3375A (es) * 1974-01-25 1975-09-15 Ciba Geigy Ag
US5436265A (en) * 1993-11-12 1995-07-25 Merck Frosst Canada, Inc. 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
WO1998011101A2 (en) * 1996-09-12 1998-03-19 Cancer Research Campaign Technology Limited Condensed n-aclyindoles as antitumor agents
AP9801302A0 (en) * 1997-07-23 2000-01-23 Pfizer Indole compounds as anti-inflammatory/analgesic agents..

Also Published As

Publication number Publication date
HK1054549A1 (en) 2003-12-05
BG107309A (bg) 2003-09-30
CA2407677A1 (en) 2002-10-28
HUP0300480A3 (en) 2006-04-28
IL152477A0 (en) 2003-05-29
JP2004501092A (ja) 2004-01-15
AR029915A1 (es) 2003-07-23
PL358877A1 (en) 2004-08-23
AU783459B2 (en) 2005-10-27
CN1431997A (zh) 2003-07-23
EE200200607A (et) 2004-04-15
AU6898401A (en) 2001-11-12
HRP20020940A2 (en) 2005-02-28
HK1054549B (zh) 2007-02-23
DE50111690D1 (de) 2007-02-01
SK15432002A3 (sk) 2004-01-08
RU2002132253A (ru) 2004-07-10
NO20025150D0 (no) 2002-10-25
HUP0300480A2 (hu) 2003-06-28
BR0110414A (pt) 2003-02-11
CN1286810C (zh) 2006-11-29
EP1276720B1 (de) 2006-12-20
US20020091124A1 (en) 2002-07-11
EP1276720A2 (de) 2003-01-22
NZ522246A (en) 2006-01-27
US20030158216A1 (en) 2003-08-21
GEP20063751B (en) 2006-02-27
WO2001082909A2 (de) 2001-11-08
CZ20023544A3 (cs) 2004-07-14
KR20030024661A (ko) 2003-03-26
IS6594A (is) 2002-10-25
NO20025150L (no) 2002-12-16
WO2001082909A3 (de) 2002-03-14
ATE348805T1 (de) 2007-01-15

Similar Documents

Publication Publication Date Title
MXPA02010627A (es) Derivados de 2-acil-indol y su uso como farmaco antitumoral.
MX2007000505A (es) Derivados de oxindol sustituidos y medicamentos que contienen los mismos.
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
MXPA02011977A (es) Herbicidas de piridina sustituidas.
MY134892A (en) Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines and their use
MX2007011695A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
RS115004A (en) Novel thiophenylglycoside derivatives,methods for production thereof, medicaments comprising said compounds and use thereof
MY139302A (en) Novel heterocyclic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
MX2007003108A (es) Compuestos imidazo-3-il-amina sustituidos y biciclicos.
GB0114286D0 (en) Nucleoside Derivatives
MY139303A (en) Novel aromatic fluoroglycoside derivatives, medicaments containing these compounds, and the use thereof
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
BG106585A (en) Kinase inhibitors as therapeutic agents
SI1585739T1 (sl) Substituirani arilciklopropilacetamidi kot aktivatorji glukokinaze
MXPA03010134A (es) Derivados de ciclohexan-1-4-diamina sustituidos.
MXPA02011370A (es) Iminoazinas substituidas.
SG151254A1 (en) Substituted morpholine and thiomorpholine derivatives
NO20052884L (no) Substituerte indolpyridinforbindelser som anti-infeksjonsmidler.
MX2007011698A (es) Derivados de oxindol sustituido, medicamentos que contienen dichos derivados y uso de los mismos.
TW200716564A (en) Tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
PL371127A1 (en) 6-aminomorphinane derivatives, method for the production and use thereof
MXPA04006266A (es) Pirimidotriazinas como inhibidores de fosfatasa.
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
YU30603A (sh) Derivati premošćenog piperazina
UA74430C2 (uk) Похідні фенілгетероциклічних етерів як інгібітори зворотного захоплення серотоніну

Legal Events

Date Code Title Description
FG Grant or registration